You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed/refractory

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))

Not yet recruiting
  • Refractory Cancer
  • Relapsed Cancer
  • Drug Sensitivity Test (DST)
  • Weston, Florida
    Lerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Suzhou, Jiangsu, China
      First Affiliated Hospital, Soochow University
    Jul 31, 2023

    Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

    Not yet recruiting
    • Relapsed/Refractory B-Cell Lymphoma
    • (no location specified)
    Jul 10, 2023

    Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Amyloid Light-chain Amyloidosis
    • (no location specified)
    Apr 20, 2023

    Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • ISB 2001
    • Benowa, Queensland, Australia
      Pindara Private Hospital
    May 18, 2023

    Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Suzhou (Selinexor, Chidamide)

    Recruiting
    • Acute Myeloid Leukemia (Relapsed/Refractory)
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jul 16, 2023

    Relapsed/Refractory B-cell Malignancies Trial (AC676)

    Not yet recruiting
    • Relapsed/Refractory B-cell Malignancies
    • (no location specified)
    Mar 27, 2023

    SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • +2 more
      • (no location specified)
      Jun 22, 2023

      Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

      Not yet recruiting
      • Relapsed/ Refractory Multiple Myeloma
      • GC012F
      • (no location specified)
      Apr 28, 2023

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • (no location specified)
      Oct 30, 2023

      Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

      Available
      • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
      • Relapsed/Refractory Acute Myeloid Leukemia
      • Magrolimab
      • (no location specified)
      Jan 18, 2023

      Relapsed/Refractory Multiple Myeloma Trial in Suzhou (Mitoxantrone HCl liposome/Dexamethasone/daratumumab)

      Recruiting
      • Relapsed/Refractory Multiple Myeloma
      • Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
      • Suzhou, Jiangsu, China
        Second Affiliated Hospital of Soochow University
      May 4, 2023

      Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

      Not yet recruiting
      • Relapsed/Refractory AML
      • Suzhou, Jiangsu, China
        The First Affiliated Hospital of Soochow University
      Mar 28, 2023

      CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

      Not yet recruiting
      • CD19-positive Relapsed or Refractory B-cell Malignancies
      • UTAA09 cells for infusion
      • +2 more
      • Hefei, Anhui, China
        The First Affiliated Hospital of USTC (AnHui Provincial Hospital
      Oct 13, 2023

      Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
      • (no location specified)
      Sep 5, 2023

      AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)

      Recruiting
      • AML
      • MDS
      • Tuebingen, Baden-Wuerttemberg, Germany
        University Hospital
      Nov 30, 2023

      Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

      Recruiting
      • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
      • thiotepa combined with pomalidomide
      • Nanjing, Jiangsu, China
        Jiangsu Province People's Hospital.
      Jun 27, 2023

      Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

      Not yet recruiting
      • Lymphoma, Primary Effusion
      • Daratumumab SC
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jun 23, 2023

      Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

      Not yet recruiting
      • Cancer
      • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
      • Fludarabine (30 mg/m^2)
      • +2 more
      • (no location specified)
      Jul 25, 2023

      Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

      Recruiting
      • Relapsed/Refractory Acute Myeloid Leukemia
      • B7-H3 target, CAR gene modified gdT cell injection
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital， Zhejiang University School of Med
      Feb 15, 2023

      Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

      Not yet recruiting
      • Relapsed/Refractory Non-Hodgkin Lymphoma
      • Duarte, California
      • +1 more
      Oct 13, 2023

      Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

      Not yet recruiting
      • Mantle-cell Lymphoma
      • Polatuzumab, bendamustin und rituximab
      • (no location specified)
      May 11, 2023

      Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

      Not yet recruiting
      • Relapsed or Refractory Non-Hodgkin's Lymphoma
      • Beijing, China
      • +3 more
      Jul 20, 2023

      Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

      Not yet recruiting
      • Refractory Multiple Myeloma
      • Relapsed Multiple Myeloma
      • Miami, Florida
        University of Miami
      May 31, 2023